Alchemedicine, Inc. (Head office: Tsukuba, Ibaraki; President: Keigo Tanaka; hereinafter “Alchemedicine”) and Asahi Kasei Pharma Corporation (Head office: Chiyoda-ku, Tokyo; President: Yoshikazu Aoki; hereinafter “Asahi Kasei Pharma”) today announced that they have entered into an exclusive license agreement to develop and commercialize Alchemedicine’s selective Endothelin A receptor antagonist (preclinical stage).

Under the terms of the agreement, Asahi Kasei Pharma has acquired worldwide exclusive rights to develop and commercialize selective Endothelin A receptor antagonist from Alchemedicine. Alchemedicine may be eligible for up to ¥35.9 billion upfront and potential development, regulatory, and commercial milestones, as well as tiered royalty payments ranging from single- to double-digits depending on sales.

The selective Endothelin A receptor antagonist is a small molecule derived from Alchemedicine’s HiSAP®¹⁾ platform and is expected to contribute to treatments for various refractory diseases which are difficult to control such as chronic kidney diseases. The selective Endothelin A receptor antagonist has indicated a potent inhibition and high selectivity for Endothelin A receptor, and shown an outstanding efficacy in animal models for chronic kidney diseases.

By creating an innovative therapeutic drug, Alchemedicine and Asahi Kasei Pharma will aim to continue to solve unmet medical needs for patients with refractory diseases.

About Alchemedicine Inc.

Alchemedicine is a biotech company focusing on the discovery of small molecule drugs using HiSAP® under a vision of “We discover life changing treatments one after another for various diseases that make a lasting positive contribution to society.”
To learn more - https://alchemedicine.com/en/ 

About Asahi Kasei Pharma Corporation

In accordance with the Asahi Kasei Pharma Mission of “to sincerely care for each individual life and solve their unmet medical needs with a wealth of ideas and solid science”, Asahi Kasei Pharma operates pharmaceutical and diagnostic businesses in the Health Care Business Unit of the Asahi Kasei Group. Asahi Kasei Pharma has developed numerous innovative drugs in the field of immunology, rare diseases, neurology, musculoskeletal disorders, and acute care, contributing to society by providing such products to patients who suffer from diseases.
To learn more - https://www.asahikasei-pharma.co.jp/en/ 

• 1)About HiSAP®